Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 17 04:00PM ET
2.32
Dollar change
-0.07
Percentage change
-2.93
%
IndexRUT P/E37.60 EPS (ttm)0.06 Insider Own23.86% Shs Outstand56.68M Perf Week-5.69%
Market Cap131.92M Forward P/E- EPS next Y-1.02 Insider Trans-29.89% Shs Float43.30M Perf Month18.97%
Income5.09M PEG16.14 EPS next Q-0.27 Inst Own62.07% Short Float17.48% Perf Quarter38.10%
Sales70.00M P/S1.88 EPS this Y88.39% Inst Trans-18.56% Short Ratio2.17 Perf Half Y-7.20%
Book/sh2.50 P/B0.93 EPS next Y-589.27% ROA3.19% Short Interest7.57M Perf Year-62.40%
Cash/sh2.68 P/C0.87 EPS next 5Y2.33% ROE4.14% 52W Range1.20 - 6.75 Perf YTD8.41%
Dividend Est.- P/FCF- EPS past 5Y-5.22% ROIC3.19% 52W High-65.63% Beta2.72
Dividend TTM- Quick Ratio9.24 Sales past 5Y- Gross Margin99.51% 52W Low94.14% ATR (14)0.16
Dividend Ex-Date- Current Ratio9.24 EPS Y/Y TTM104.65% Oper. Margin-5.72% RSI (14)55.34 Volatility4.13% 4.65%
Employees24 Debt/Eq0.15 Sales Y/Y TTM- Profit Margin7.27% Recom1.00 Target Price10.67
Option/ShortYes / Yes LT Debt/Eq0.13 EPS Q/Q378.68% Payout- Rel Volume0.22 Prev Close2.39
Sales Surprise100.00% EPS Surprise4479.44% Sales Q/Q- EarningsMay 12 AMC Avg Volume3.48M Price2.32
SMA200.87% SMA5023.14% SMA200-11.56% Trades Volume775,586 Change-2.93%
Date Action Analyst Rating Change Price Target Change
Jul-31-24Initiated Raymond James Outperform $20
Jul-14-23Initiated Piper Sandler Overweight
Jun-30-23Upgrade Stifel Hold → Buy $2 → $10
Jun-28-23Upgrade H.C. Wainwright Neutral → Buy $11
Jun-27-23Upgrade Wedbush Neutral → Outperform $10
Mar-29-22Downgrade Wedbush Outperform → Neutral
Mar-22-22Downgrade H.C. Wainwright Buy → Neutral
Sep-30-21Initiated Stifel Hold $10
Jan-07-21Initiated Wedbush Outperform $45
Nov-24-20Initiated Berenberg Buy $58
May-29-25 08:00AM
May-12-25 04:05PM
Apr-26-25 11:00AM
Mar-31-25 08:00AM
Mar-25-25 12:58AM
10:42AM Loading…
Mar-20-25 10:42AM
Mar-19-25 07:00AM
Mar-06-25 04:09PM
04:01PM
Feb-19-25 09:15AM
Jan-12-25 06:05AM
Nov-05-24 09:00AM
08:00AM
Nov-01-24 08:00AM
Oct-07-24 04:01PM
11:43AM Loading…
Sep-23-24 11:43AM
07:00AM
Sep-22-24 10:00AM
Sep-14-24 03:30AM
Aug-08-24 04:05PM
12:00PM
Aug-06-24 01:53PM
07:37AM
07:30AM
Jun-29-24 08:28PM
06:30PM
Jun-01-24 10:00AM
May-29-24 08:00AM
May-16-24 08:23AM
May-10-24 08:46AM
01:54PM Loading…
May-09-24 01:54PM
07:30AM
07:28AM
Apr-29-24 08:50AM
Apr-25-24 09:55AM
Apr-24-24 04:05PM
Apr-23-24 07:45AM
Apr-15-24 12:00PM
Apr-11-24 08:00AM
Apr-08-24 09:55AM
Apr-07-24 06:00PM
Apr-03-24 08:00AM
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
08:00AM
Mar-05-24 04:30PM
Feb-28-24 08:00AM
Jan-04-24 08:00AM
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
Sep-18-23 12:34PM
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
07:30AM
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-26-22 08:00AM
Sep-06-22 08:00AM
Aug-28-22 09:41AM
Aug-09-22 08:00AM
Aug-03-22 08:00AM
Aug-01-22 08:55AM
Jul-02-22 08:29AM
Jun-06-22 08:00AM
Jun-01-22 07:00AM
May-17-22 07:00AM
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH GROWTH N V10% OwnerMar 19 '25Sale2.075,784,29211,997,7492,733,547Mar 20 09:01 PM
Versant Venture Capital VI, L.10% OwnerAug 28 '24Sale6.32221,6001,400,5563,726,341Aug 30 04:16 PM
David EpsteinFormer EmployerJul 31 '24Proposed Sale6.2050,000310,000Jul 31 04:18 PM
David EpsteinFormer EmployeeJul 26 '24Proposed Sale6.2050,000310,000Jul 26 05:54 PM